glp 1 agonist statpearls Top GLP-1 Agonists Balance Weight Loss Efficacy, Safety GLP-1 Agonists: Uses, Side Effects

Tirzepatides dual GIP/GLP 1 mechanism appears even more potent

Reasons for low levels of initiation and long-term use of AOMs may include reluctance of public health and medical organizations to recognize obesity as a disease, lack of reimbursement, provider inexperience, and misperceptions about the efficacy and safety of available treatments

In 2022, a modified version of the GLP-1/GIP dual agonist, tirzepatide (Zepbound), developed by Eli Lilly induced an average weight loss of 21% in humans with obesity and 15% weight loss in obese patients with diabetes (1)

This gives them a number of injectable and oral GLP-1 candidates, which are expected to begin clinical trials soon

[DOI] [PubMed] [Google Scholar] 8.Ferro EG, Michos ED, Bhatt DL, Lincoff AM, Elshazly MB

Sourcing Statement RawBiotix sources all research compounds from U.S.-based, GMP-certified and ISO-accredited laboratories, with each batch 98%+ purity, third-party verified